GBNH(Delisted)
Greenbrook TMSยทNASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GBNH
Greenbrook Tms Inc.
A leading provider of FDA-cleared, non-invasive therapies for Major Depressive Disorder and other mental health disorders in the United States
890 Yonge Street, 7th Floor, Toronto, Ontario, Canada M4W 3P4
--
Greenbrook TMS Inc. was incorporated in Ontario, Canada on February 9, 2018 under the OBCA. They are the leading providers of transcranial magnetic stimulation (TMS) therapy in the United States for the treatment of major depressive disorder (" MDD ") and other mental health disorders. The Company's predecessor, TMS NeuroHealth Centers, Inc., was established in 2011 to take advantage of the opportunities created by the conversion technology of TMS, an FDA-approved non-invasive therapy for the treatment of MDD. Their business model takes advantage of the opportunity to deliver a new, differentiated service channel for TMS - patient-centric, making TMS treatment easily accessible to all patients while maintaining a high level of care.
Company Financials
EPS
GBNH has released its 2024 Q3 earnings. EPS was reported at -0.29, versus the expected -0.09, missing expectations. The chart below visualizes how GBNH has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
GBNH has released its 2023 Q3 earnings report, with revenue of 18.04M, reflecting a YoY change of -13.09%, and net profit of -12.75M, showing a YoY change of 24.04%. The Sankey diagram below clearly presents GBNH's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
